Request a Quote |

Cyprotex commences drug development relationship with Avidex

Cyprotex (LSE: CRX) today announces that it has entered into a preclinical agreement with Avidex, the Oxford-based company that develops products for cancer and autoimmunity. The objective of the agreement is to optimise a successful candidate drug that inhibits the interaction of CD80 with CD28 on T cells and blocks T cell activation.

In this working relationship, Cyprotex will provide all the technologies and expertise necessary to evaluate and optimise the pre-clinical properties of Avidex's small molecule lead compounds.

Commenting on the collaboration, Dr David Leahy, Chief Scientific Officer of Cyprotex, said: "This project is recognition of the value of our integrated approach that addresses the major issues regarding the behaviour of drugs in the human body that will aid the selection of the best lead candidate. We are pleased to be working with Avidex and look forward to applying our extensive technology and expertise to the development of an exciting new product."

Dr David McGibney, Director of Drug Discovery & Development at Avidex, said: "We have selected Cyprotex to facilitate our development programme because we know they can provide the essential insight that is central to the continuation of our CD80 antagonist programme."

For further information:

Dr David Leahy, Chief Scientific Officer
Cyprotex PLC

Tel: +44 (0) 1625 505 100

Neill Mackenzie, Chief Business Officer
Avidex Limited

Tel: +44 (0) 1235 438600

Media enquiries:

For Cyprotex: Bankside Consultants Limited
Henry Harrison-Topham/ Heather Salmond

Tel: +44 (0) 20 7444 4140

For Avidex: HCC Defacto
Chris Gardner

Tel: +44 (0) 207 4963300

Contact us

News categories


Contact us to discuss your ADME Tox issues or request a quote

North America (East Coast): +1-888-297-7683
Europe: +44 (0)1625 5051000


or fill out the form below:

Please give details of the assays you are interested in. Where appropriate please specify one or more species (human, rat, mouse etc.), isoforms (CYP1A1,CYP1B1, etc) or other relevant details.

By clicking on ‘Send’ I agree that my data is being transferred and used by Cyprotex and the affiliated Evotec Group. The Evotec Group currently consists of the following companies. For further details please see our privacy policy.

If you would like to be kept informed of our latest services, new research, events and other news please tick the box below: